43 Amino Acids · Full Protein Research Compound · WADA Prohibited Endogenous — Present in All Mammalian Cells

Thymosin β4

Tβ4 · TB4 · T-β-4 · Parent molecule of TB-500

"The most abundant intracellular peptide in most mammalian cells — TB-500 is derived from its most active region. While TB-500 captures the actin-regulatory mechanism, the full Thymosin β4 protein adds cardiac regeneration, corneal healing, angiogenesis, and broader immunomodulatory functions that the fragment cannot replicate."

Structure
43 amino acids · 4,964 Da · endogenous
vs TB-500
TB-500 = Tβ4(17-23) fragment · actin binding region only
Key cardiac data
Activates epicardial progenitors after MI in mice
Corneal data
FDA Fast Track designation — corneal wound healing
WADA
Prohibited at all times
Origin & Background

The complete molecule — beyond what TB-500 can do

Thymosin β4 (Tβ4) is a 43-amino acid, 4,964 Da peptide — the most abundant intracellular actin-sequestering protein in most mammalian cells. It was first isolated from thymic tissue but is now known to be expressed ubiquitously. Every cell in the body uses it to regulate the equilibrium between monomeric G-actin and filamentous F-actin — the dynamic balance that governs cell shape, motility, and division.

TB-500 (the most widely used research peptide for tissue repair) is a synthetic fragment derived from the actin-binding region of Tβ4, specifically amino acids 17-23 (LKKTETQ). TB-500 captures the primary actin-sequestering mechanism and is more stable and practical than the full protein. However, Tβ4 has multiple functional domains beyond the actin-binding sequence: N-terminal domains involved in cardiac progenitor activation, C-terminal sequences relevant to corneal healing, and middle domains that interact with integrin-linked kinase (ILK) and drive angiogenesis. None of these are present in TB-500.

The most compelling Tβ4 research goes beyond tissue repair. The Bhattacharya lab (UCL) demonstrated that Tβ4 activates dormant epicardial progenitor cells after myocardial infarction in mice — priming them to regenerate cardiac muscle. RegeneRx Biopharmaceuticals ran a Phase 1/2 clinical programme for Tβ4 in corneal wound healing, receiving FDA Fast Track designation, before funding constraints halted development.

Tβ4 vs TB-500 — which to use: TB-500 is more practical for tissue repair (more stable, better characterised for that application, cheaper). Full Tβ4 is theoretically better if the goal includes cardiac regeneration potential, corneal healing, or the full angiogenic mechanism — but the practical differences in human protocols are not well-characterised. Most community users use TB-500 for convenience; full Tβ4 is rarer and more expensive.

Science & Mechanism

Multiple domains, multiple mechanisms

Mechanism of Action

1
Actin sequestration (shared with TB-500): The LKKTETQ sequence (Tβ4 17-23) binds G-actin monomers, maintaining the cellular pool of unpolymerised actin available for dynamic cytoskeletal remodelling. This enables cell migration to injury sites, cell division, and tissue repair. This is TB-500's mechanism — but it is only one of Tβ4's.
2
ILK (Integrin-Linked Kinase) activation: Tβ4 interacts with ILK, activating downstream signalling that promotes endothelial cell differentiation and migration — the primary mechanism driving Tβ4-induced angiogenesis. New blood vessel formation is essential for healing tissue that lacks vasculature.
3
Epicardial progenitor activation (cardiac): This is Tβ4's most extraordinary property. After myocardial infarction, dormant epicardial cells can be reprogrammed into cardiac muscle cells by Tβ4. This does NOT occur with TB-500 — it requires the full protein. Bhattacharya (2011) demonstrated that priming with Tβ4 before MI activated these progenitors, and re-treatment after MI induced their differentiation into cardiomyocytes.
4
Corneal wound healing: Tβ4 stimulates re-epithelialization of the cornea through promoting corneal epithelial cell migration, reducing inflammation, and stimulating angiogenesis in the limbal region. RegeneRx's Phase 1/2 corneal programme (RGN-259, ophthalmic Tβ4) showed improved healing vs standard care.
5
Anti-inflammatory and NF-κB suppression: Tβ4 inhibits NF-κB-mediated inflammatory gene expression, reducing inflammatory cytokine production at injury sites. This anti-inflammatory effect complements the repair mechanisms rather than suppressing the immune response needed for healing.
Community Voices

What people report

Anecdotal ReportNot medical evidence · Research use

"Ran a cycle of full Tβ4 alongside TB-500 for a shoulder injury. Hard to separate the two. Recovery was faster than previous similar injuries. The reason I used both was specifically for the cardiac benefits Tβ4 might provide that the fragment can't — I have a family history of heart disease."

Male, 48. The cardiac rationale for using full Tβ4 rather than TB-500 alone is the most commonly articulated community reason for the higher cost and lower availability. Whether the cardiac progenitor activation seen in mouse MI models translates to any meaningful cardiac benefit in healthy humans is not established.

Anecdotal ReportNot medical evidence · Research use

"Used Tβ4 eye drops (ophthalmic preparation) for dry eye and a corneal abrasion. The healing was notably faster than usual and the dryness improved significantly over 3 weeks. The ophthalmic application seems well-documented and this is the use case I'm most confident about."

Female, 44. Ophthalmic Tβ4 application is the use case with the strongest clinical evidence base — RegeneRx's Phase 1/2 programme specifically studied this route. Corneal and dry eye applications are the most evidence-supported practical use of Tβ4 in humans.

Benefits & Evidence

What the data shows

❤️
Cardiac progenitor activation
Bhattacharya (2011, Nature): Tβ4 pretreatment activated dormant epicardial progenitor cells; post-MI treatment induced differentiation into cardiomyocytes. Demonstrated in mouse MI models. Bhattacharya group published follow-up data through 2023 extending these findings. Human translation not yet demonstrated.
● Moderate — compelling mouse data · no human trials
👁️
Corneal wound healing
RegeneRx Phase 1/2 (RGN-259): ophthalmic Tβ4 solution showed improved corneal healing vs standard care. FDA Fast Track designation granted. Development paused due to funding. 2025 publication: engineered tandem Tβ4 peptide promoted corneal wound healing in preclinical models.
● Moderate — Phase 1/2 human data + FDA Fast Track
🩹
Tissue repair and healing
Multiple preclinical studies across tissue types (tendon, muscle, cardiac, corneal). Injectable Tβ4-modified hyaluronic acid with exosomes (ACS Nano 2025): promoted stem cell homing for regeneration. The full protein adds ILK-mediated angiogenesis to the actin mechanism TB-500 provides.
● Moderate — preclinical + small human data
Safety First

Risks & considerations

⚠️
Similar safety profile to TB-500 — endogenous molecule, generally well tolerated in research. The RegeneRx clinical programme found ophthalmic Tβ4 safe with no serious adverse events. Injectable systemic use has less human safety data. WADA prohibition is the main practical concern for athletes.
Mild
Injection site reactions — mild, transient redness and swelling. Common with SubQ administration as with all injectable peptides.
Serious
WADA prohibited at all times — as a peptide hormone and growth factor, Tβ4 is prohibited in competition. Detection methods exist.
Unknown
Cardiac progenitor activation in healthy adults — activating epicardial progenitors in a heart without acute MI injury has not been studied. The theoretical concern of inappropriate cardiac remodelling in healthy subjects is uncharacterised.
Synergy Stack

Complementary to TB-500 or standalone

💊 Most evidence-supported use
Ophthalmic use (corneal/dry eye)
Tβ4 ophthalmic solution · RGN-259 concentration range
Moderate evidence
The use case with the best human evidence base — Phase 1/2 data, FDA Fast Track, and a 2025 engineered Tβ4 publication confirming corneal wound healing promotion. If exploring Tβ4, this is the most clinically justified application.
TB-500 as base · Tβ4 as complement
TB-500 for general tissue repair · Tβ4 for cardiac/corneal goals
Moderate evidence
TB-500 handles the actin mechanism (more stable, better characterised, cheaper). Adding full Tβ4 makes sense when the specific goals include cardiac regeneration potential, corneal healing, or the complete ILK/angiogenic mechanism that the fragment cannot provide.
⏱ Protocol Notes
Community protocols typically mirror TB-500 protocols: 2-4mg SubQ twice weekly for 4-6 week loading phase, then 1-2mg weekly for maintenance. Ophthalmic use: 1-2 drops in affected eye 2-4× daily as per preparation concentration.
Honest Assessment

Editor's summary

Thymosin β4 is TB-500's parent — the complete molecule from which the most popular research peptide derives its actin-regulatory mechanism. The additional functional domains of the full protein — particularly cardiac progenitor activation and corneal healing — give Tβ4 a scope of action that TB-500 genuinely cannot replicate. The Nature 2011 cardiac progenitor paper is one of the most exciting findings in regenerative medicine of the last 15 years.

The practical reality: most of what community users want from Tβ4 is delivered adequately by TB-500, which is cheaper, more stable, and better characterised for tissue repair applications. Full Tβ4 makes specific sense for ophthalmic applications (best evidence base, practical delivery route) and for people specifically interested in the cardiac progenitor mechanism. The gap between the extraordinary mouse cardiac data and any human clinical evidence for cardiac regeneration is still very large.

Verdict
"The complete molecule with additional cardiac and corneal mechanisms TB-500 cannot provide. Most tissue repair goals are well-served by TB-500 alone. Full Tβ4 is specifically indicated for ophthalmic applications (best evidence) and for those targeting the cardiac progenitor mechanism. The Nature cardiac data is extraordinary — the human translation is still unproven."